AryoGen

AryoGen Pharmed (Persian: آریوژن فارمد) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]

AryoGen
Company typePrivate Company
IndustryPharmaceutical
Founded2009
Headquarters,
Area served
Worldwide
Key people
Fereidoun Mahboudi
Chairman
Productsbiopharmaceuticals, Monoclonal antibody
Revenue US$ 100 million
Number of employees
300+ (2015)
WebsiteAryoGen

History

AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was spun off a Biopharmaceutical company, which formed a new entity named AryoGen Pharmed which started its production in 2011. It was deemed an issue of national interest. AryoGen changed its name to AryoGen Pharmed in 2016.

AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified.[4]

Products

AryoGen's products include:

AryoSeven is now approved by Iranian food and drug organisation and from August 2012 is in the market.

AryoGen Pharmed Complex.

See also

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.